观点:在抗脂综合征中引起的血栓形成
Denis Wahl1, Vittorio Pengo2,3
1Université de Lorraine, CHRU-Nancy, Vascular Medicine and Rare Vascular Diseases Division, and National Referral Center for Systemic Autoimmune Diseases, Inserm, UMR 1116 DCAC, Nancy, France.
Rheumatology (Oxford, England)
|February 6, 2024
概括
引起静脉血栓栓塞 (VTE) 的抗脂综合征 (APS) 患者需要仔细评估有限的抗凝剂. 关于APS血栓形成的治疗持续时间的决定应该由患者和医生共同决定.
科学领域:
- 医学研究 医学研究
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 未引起的血栓形成是抗脂综合征 (APS) 的标志.
- 引起的静脉血栓塞栓症 (VTE) 与一般人群中未引起的静脉血栓塞栓症具有不同的特征.
- 在APS患者中引起的VTE的管理,特别是关于抗凝固时间的管理,仍然不清楚.
研究的目的:
- 评估在经历引起VTE的APS患者中限制抗凝治疗持续时间的标准.
- 强调需要基于临床和实验室发现的个性化治疗决策.
- 突出患者和医生之间共同决策的重要性.
主要方法:
- 对APS患者的临床特征和实验室评估的审查.
- 对抗脂抗体 (aPL) 资料的分析.
- 在患有动脉血栓症的患者中评估心血管风险因素.
主要成果:
- 关于在APS中引起VTE的抗凝血治疗持续时间的数据有限.
- 心血管风险因子控制目前不支持停止抗凝血药物治疗APS的动脉血栓形成.
- 对临床和实验室数据的个案分析对于治疗决策至关重要.
结论:
- 仔细的临床和实验室评估至关重要,以确定APS患者在引起VTE后有资格接受有限的抗凝药.
- 关于抗凝血剂的风险和益处的共同决策至关重要.
- 长期抗凝药通常用于APS的动脉血栓形成,需要个性化评估.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Disorders of Hemostasis
915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525


